Combinatorial effects of metformin and glucose on the immune evasion of breast cancer 4T1 cells
DOI:
https://doi.org/10.15419/bmrat.v10i10.835Keywords:
Anti-cancer, Breast cancer, Glucose, Metformin, Tumorigensis, Type 2 diabetesAbstract
Introduction: Metformin is one current medicine used to treat type 2 diabetes. Numerous studies have shown that high metformin concentrations have an anti-cancer effect. Therefore, this study aimed to examine whether combining various metformin and glucose concentrations affects mouse breast cancer cell proliferation, migration, and expression of immune escape-related genes.
Methods: This study assessed 12 glucose and metformin combinations: four glucose concentrations (0, 0.5, 1.0, and 4.5 g/L) and three metformin concentrations (0, 2.0, and 5.0 mM). Mouse breast cancer 4T1 cells were cultured in RPMI 1640 media containing these 12 combinations at 37?C with 5% CO2. The combinatorial effects of metformin and glucose were evaluated based on 4T1 cell proliferation, migration, and expression of immune escape-related genes.
Results: Combining 2 mM metformin with 4.5 g/L glucose concentration inhibited 4T1 cell proliferation, migration, and expression of immune escape-related genes.
Conclusion: Our findings provide more information about the anticancer effects of metformin under high glucose conditions, help explain why metformin effectively treats cancer in patients with type 2 diabetes, and suggest combining metformin with glucose in anticancer treatment.
Published
Issue
Section
License
Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
